It is a long established fact that a reader of a page when looking at its layout.

    IRVINE, Calif., June 10, 2021 /PRNewswire/ — Predictive Health Diagnostics Company, Inc. (“PHDC” or “the Company”), a diagnostics platform company that develops, manufactures, and distributes specialty diagnostic tests combining science, technology, and proprietary analytics to detect diseases with significant unmet medical needs, today announced the North American launch of its second diagnostic test, DIABETESpredictâ„¢, in collaboration with distribution partner Patia Europe SL (“Patia”).

    Predictive Health Diagnostics Company (PRNewsfoto/Predictive Health Diagnostics Company)
    DIABETESpredictâ„¢ is a polygenic laboratory test that provides a high-sensitivity and specificity evaluation of an individual’s genetic predisposition to develop type 2 diabetes (T2D) and offers personalized recommendations based on the patient’s genetic profile. The test is for individuals of any age concerned about their risk of developing diabetes, especially those with a family history of diabetes or risk factors associated with risk of diabetes like mothers with a history of gestational diabetes, obese individuals, and individuals with metabolic abnormalities.

    The test was developed by Patia in collaboration with scientists and endocrinologists at The Massachusetts General Hospital (Boston, MA) and The Broad Institute of MIT & Harvard (Cambridge, MA). Licensed by Predictive Health Diagnostics Company in 2020, the Company recently entered into an exclusive agreement with Patia for distribution of the product throughout North America.

    “Our mission is to greatly reduce the number of deaths from type 2 diabetes by making DIABETESpredict a clinical standard for prevention of diabetes. DIABETESpredict is the only test of its kind that can identify type 2 diabetes risk before symptoms or abnormal lab results are discovered. Physicians and patients receive genotype-informed recommendations that can guide decisions for effective T2D prevention and intervention,” said Matthew Nuñez, Chief Executive Officer of Predictive Health Diagnostics Company. “We are pleased to be working with Patia, the original developer of DIABETESpredict, to distribute the product in the U.S., where a staggering one in three individuals are eligible for the test. Through our exclusive agreement with Patia, Predictive Health Diagnostics Company plans to pursue distribution of the test in other key international markets.”

    Healthcare providers may place orders for DIABETESpredict by calling 866-299-8998.

    PHDC also offers the PULS Cardiac Testâ„¢, a one-of-a-kind diagnostic blood test that identifies asymptomatic patients at risk of a heart attack who are missed by the current standard of care. Test results determine a risk score that quantifies coronary artery inflammation and predicts an individual’s risk of a heart attack in the next five years, a time frame during which preventative cardiology and lifestyle changes can take effect successfully. Cardiac disease is the number one cause of death worldwide, affecting over 120 million Americans.

    About Predictive Health Diagnostics Company

    Predictive Health Diagnostics Company (PHDC) is a leading specialty diagnostics development platform company that develops, manufactures, and distributes medical tests combining science, technology, and proprietary analytics to detect high-risk diseases with significant unmet medical needs. PHDC’s laboratory information systems use data from multiple sources including proteomics, genetics, metabolics, biochemistry, phenotype, and imaging to address among the most challenging clinical problems. To learn more, visit PHDC at, Twitter, Facebook, and LinkedIn.

    About Patia Europe SL

    Patia is a Public Health company that integrates genetic, metabolomic and digital tools to facilitate the prevention and control of type 2 diabetes. Patia’s team has extensive experience in the fields of molecular biology and genomic medicine. Their knowledge is complemented by top-level alliances with prestigious research centres in Europe and the Americas to make the most advanced genomic and technological tools available to the population in the most accessible way.

    Forward-Looking Statements

    Forward-looking statements are based on our current expectations and assumptions regarding our business, our industry, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you therefore against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance.

    Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.